Resources from the same session
847O - Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase III trial
Presenter: Chaosu Hu
Session: Proffered paper session: Head and neck cancer
Resources:
Abstract
Slides
Webcast
LBA35 - Primary results from TACTI-003: A randomized phase IIb trial comparing eftilagimod alpha (soluble LAG-3) plus pembrolizumab versus pembrolizumab alone in first-line recurrent or metastatic head and neck squamous cell carcinoma with CPS ≥1
Presenter: Claus Kristensen
Session: Proffered paper session: Head and neck cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant 847O and LBA35
Presenter: Hisham Mehanna
Session: Proffered paper session: Head and neck cancer
Resources:
Slides
Webcast
Q&A
Session: Proffered paper session: Head and neck cancer
Resources:
Webcast
849O - Phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent/metastatic salivary gland cancer: Results from the MYTHOS trial
Presenter: Ichiro Kinoshita
Session: Proffered paper session: Head and neck cancer
Resources:
Abstract
Slides
Webcast
LBA36 - A randomised phase II study to evaluate the efficacy and safety of androgen deprivation therapy (ADT) vs chemotherapy (CT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancers
Presenter: Laura Locati
Session: Proffered paper session: Head and neck cancer
Resources:
Abstract
Slides
Webcast
Q&A
Session: Proffered paper session: Head and neck cancer
Resources:
Webcast